Global Blood Therapeutics, Inc. (GBT)
(Delayed Data from NSDQ)
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[GBT]
Reports for Purchase
Showing records 21 - 40 ( 340 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Q1: Looking Ahead to Oxbryta Growth in H2 & Upcoming ''601 Catalysts
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Industry: Medical - Biomedical and Genetics
Q1: Looking Ahead to Oxbryta Growth in H2 & Upcoming ''601 Catalysts
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Becoming the SCD Management Company; Assuming at OUTPERFORM & $71 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
GBT601 and Inclacumab Could Transform Sickle Cell Clinical Paradigm; Reit. Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Q4/FY21: Oxbryta Sales Hold Up as Pandemic Persists; ''601 Data in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Oxbryta 12 yo+ Gains EU Approval Expanding Access to Additional 52K Patients
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Rounding Out a Strong 2021: Oxbryta 4-<12 yo Approval, 12 yo+ Pos. CHMP Opinion
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L